Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine?

Table 3

Table of excluded studies and reasons for exclusion.

Study name	Design, country	Sample size	Reasons for exclusion
Nambozi et al., 2011 [36]	RCT, Zambia	304	The study has been reported as part of the larger multicentric study of Bassat et al., 2009, already included in the review
Arinaitwe et al., 2009 [15]	RCT, Uganda	351	Some of the study participants were infected with other species of Plasmodium. The reviewer was only interested in primary studies in which only P. falciparum infections were treated.
Verret et al., 2011 [37]	RCT, Uganda	292	This study is a subanalysis of the main study of Arinaitwe et al., 2009, which was also excluded from the review with reasons as the above.
Katrak et al., 2009 [38]	RCT, Uganda	246	There was no data on treatment failure; only adverse events were presented. The main aim of the study was to investigate safety of study drugs among HIV-infected and HIV-uninfected children, which is not relevant for this review.